Never miss the latest news and offers - subscribe now!
This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters.
Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.
David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.
Participants will be able to:
David Haylock, CEO VivaZome Therapuetics
Business Development Manager, Pall Corporation
The iCELLis bioreactor system is an automated, single-use, fixed-bed bioreactor that provides excellent cell growth conditions for adherent cells.